Unknown

Dataset Information

0

Understanding molecular consequences of putative drug resistant mutations in Mycobacterium tuberculosis.


ABSTRACT: Genomic studies of Mycobacterium tuberculosis bacteria have revealed loci associated with resistance to anti-tuberculosis drugs. However, the molecular consequences of polymorphism within these candidate loci remain poorly understood. To address this, we have used computational tools to quantify the effects of point mutations conferring resistance to three major anti-tuberculosis drugs, isoniazid (n?=?189), rifampicin (n?=?201) and D-cycloserine (n?=?48), within their primary targets, katG, rpoB, and alr. Notably, mild biophysical effects brought about by high incidence mutations were considered more tolerable, while different structural effects brought about by haplotype combinations reflected differences in their functional importance. Additionally, highly destabilising mutations such as alr Y388, highlighted a functional importance of the wildtype residue. Our qualitative analysis enabled us to relate resistance mutations onto a theoretical landscape linking enthalpic changes with phenotype. Such insights will aid the development of new resistance-resistant drugs and, via an integration into predictive tools, in pathogen surveillance.

SUBMITTER: Portelli S 

PROVIDER: S-EPMC6193939 | biostudies-literature | 2018 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Understanding molecular consequences of putative drug resistant mutations in Mycobacterium tuberculosis.

Portelli Stephanie S   Phelan Jody E JE   Ascher David B DB   Clark Taane G TG   Furnham Nicholas N  

Scientific reports 20181018 1


Genomic studies of Mycobacterium tuberculosis bacteria have revealed loci associated with resistance to anti-tuberculosis drugs. However, the molecular consequences of polymorphism within these candidate loci remain poorly understood. To address this, we have used computational tools to quantify the effects of point mutations conferring resistance to three major anti-tuberculosis drugs, isoniazid (n = 189), rifampicin (n = 201) and D-cycloserine (n = 48), within their primary targets, katG, rpoB  ...[more]

Similar Datasets

| S-EPMC3305424 | biostudies-literature
| S-EPMC3957771 | biostudies-literature
| S-EPMC4068477 | biostudies-literature
| S-EPMC163747 | biostudies-other
| S-EPMC6779907 | biostudies-other
2009-04-04 | GSE15540 | GEO